Stem Cell Services
Cellaria offers the most advanced and comprehensive stem cell services available today. Our single source service offerings include RNA-mediated iPS cell line generation, maintenance, and differentiation to enable the development of next generation disease models.
These disease models are used for pathway biology, drug development, assessing molecular and pharmacological mechanisms of action – with long-term potential application in the development of the next generation of personalized therapies.
RNA has proven to be the most efficient and clinically relevant reprogramming platform for the generation of human iPS cell lines from human skin fibroblasts and peripheral and cord blood endothelial progenitor cells. The combination of this platform and our expertise ensures the delivery of high quality iPS cell lines to meet your specific needs.
Our Technical Edge
We combine a team of experts who have over 20 years of experience in RNA-iPS cell biology and provide a single source solutions for your iPSC needs: primary patient cell culture establishment, RNA reprogramming, iPSC line expansion/banking, characterization and differentiation.
• RNA reprogramming service offerings
Integration-free, non-viral , safe and efficient
• Differentiation service offerings
Readily available lineages coupled with flexible, efficient and iterative custom solutions
• Consultative science
Industry leading scientific experts will help to develop a cost effective and milestone driven project to meet your needs
• Concierge customer and technical support
Start-to-finish assistance and support throughout entire process
Primary Patient Sample Cell Line Establishment (3-4 weeks)
Cellaria will work with you to identify and select the proper patient sample source to fit your specific research program needs.
- Fibroblasts from skin punch or EPCs from blood
- Human Pathogen Panel and mycoplasma testing
- 3-4 vials (1e6 cells per vial)
RNA Reprogramming (2-6 weeks)
Our team utilizes novel RNA reprogramming technologies that allow for the generation of clinically-compliant and integration-free human iPSCs from human fibroblasts and endothelial progenitor cells in as little as two weeks. Use of non-integrating RNA technology ensures that your iPS cell lines have never been exposed in vitro to retained viral programs or DNA vectors that may result in genomic integration/alteration.
Expansion and Banking of Primary
Patient Cells (3-4 weeks)
Cellaria’s expansion and banking protocols incorporate xeno- and feeder free cell culture substrates, culture and cryopreservation media to ensure consistent, high viability cell cultures upon thaw. Derived iPS cell lines can be expanded and banked to meet alternate customer specifications.
Basic Characterization (1-4 weeks)
Cellaria’s core services include ICC or FACS to ensure pluripotency expression, mycoplasma/pathogen screening to ensure sterility and fingerprinting analysis to ensure iPSC identity. Additional services include karyotyping to assess genomic stability, qRT-PCR of pluripotency genes or tri-lineage differentiation to assess in vitro pluripotential.
For specialized support, Cellaria extends beyond basic characterization services to be inclusive of in vivo teratoma formation assay or directed differentiation to terminal cell type.
Cellaria industry-leading expertise in iPS cell modeling allows for the most flexible, adaptable and customizable solutions for your differentiated cell type of interest. Our stage specific targets combined with consistent scientific communication throughout project, ensures an efficient and tailored process. Current cell types offered include, but are not limited to:
- Neural Progenitor Cells (NPCs) 1-2 months
- Cortical, Dopaminergic, Motor Neurons 2-3 months
- Hepatocyte Cells 1-2 months
- Cardiomyocytes 1-2 months
Connect With Us
Learn more about how Cellaria can help transform your research efficacy.